Clinical trials with new oral anticoagulants: Additive value of indirect comparisons also named network meta-analyses

Hamostaseologie

Volumn 33, Issue 1, 2013, Pages 62-70

  Harenberg, Job ^a   Weiss, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Oral anticoagulants; Prophylaxis of thromboembolism; Rivaroxaban; Total hip replacement; Total knee replace ment

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ENOXAPARIN; RIVAROXABAN; WARFARIN;

CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; META ANALYSIS (TOPIC); REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84873589781     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-12-11-0021     Document Type: Review

References (53)

1. Roskell NS, Lip GY, Noack H et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
2. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147: 590-592.
3. Lip GY, Andreotti F, Fauchier L et al. Bleeding risk assessment and management in atrial fibrillation patients. Thromb Haemost 2011; 106: 997-1011.
4. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133(6 Suppl): 160S-198S.
5. Ogilvie IM, Newton N, Welner SA et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645
6. Tasker A, Harbord R, Bannister GC. Meta-analysis of low molecular weight heparin versus placebo in patients undergoing total hip replacement and post-operative morbidity and mortality since their introduction. Hip Int 2010; 20: 64-74.
7. Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e278S-325S.
8. Linkins LA, Dans AL, Moores LK et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e495S-530S.
9. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008; 34: 39-57.
10. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
11. Connolly SJ, Ezekowitz MD, Yusuf S et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
12. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
13. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
14. Glenny AM, Altman DG, Song F et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1-134.
15. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-2324.
16. Ades AE, Madan J, Welton NJ. Indirect and mixed treatment comparisons in arthritis research. Rheumatology 2011; 50 (Suppl 4): iv5-9.
17. Cooper NJ, Sutton AJ, Morris D et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Stat Med 2009; 28: 1861-1881.
18. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
19. Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part1 Value Health. 2011; 14: 417-428.
20. Hoaglin DC, Hawkins N, Jansen JP et al. Conducting indirect-treatment-comparison and networkmeta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269.
22. Harenberg J, Marx S, Diener HC et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012; 31: 330-339.
23. Lip GY, Larsen TB, Skjøth F et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention inatrial fibrillation. J Am Coll Cardiol 2012; 60: 738-746.
24. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
25. Wells GA, Coyle D, Cameron C et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. www.cadth.ca/media/pdf/ NOAC_Therapeutic_Review_final_report.pdf (assessed Dec 22, 2012).
26. Harenberg J, Marx S, Wehling M. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thromb Haemost 2012; 108: 407-409.
27. Schneeweiss S, Gagne JJ, Patrick AR et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5: 480-486.
28. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology. Europace 2010; 12: 1360-1420.
29. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest 2012; 141: e531S-575S.
30. Harenberg J, Lip GY. Differences between indirect comparison studies of the oral anticoagulants for stroke prevention in atrial fibrillation: where do we go next? QJM 2013; 106: 95-96.
31. Testa L, Agnifili M, Latini RA et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012; 105: 949-957.
32. Miller CS, Grandi SM, Shimony A et al. Metaanalysis ofefficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-460.
33. Dentali F, Riva N, Crowther M et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-2391.
34. Rasmussen LH, Larsen TB, Graungaard T et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012; 345: e7097.
35. Alonso-Coello P, Zhou Q, Guyatt G. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison. Thromb Haemost 2012; 108: 647-653.
36. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J 2010; 51: 113-123.
37. Lereun C, Wells P, Diamantopoulos A et al. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ 2011; 14: 238-244.
38. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011; 36: 111-124.
39. Cohen A, Drost P, Marchant N et al. The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement: Systematic Review and Network Meta-Analysis. Clin Appl Thromb Hemost 2012; 18: 611-627.
40. Dahl OE, Quinlan DJ, Bergqvist D et al. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 2010; 8: 1966-1975.
41. Maratea D, Fadda V, Trippoli S, Messori A. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost 2011; 9: 1868-1870.
42. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344: e3675.
43. Harenberg J, Marx S, Dahl OE et al. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost 2012; 108: 903-912.
44. Hamid JS, Meaney C, Crowcroft NS, Granerod J, Beyene J; UK Etiology of Encephalitis Study Group. Cluster analysis for identifying sub-groups and selecting potential discriminatory variables in human encephalitis. BMC Infect Dis 2010; 10: 364-374.
45. Song EK, Moser DK, Rayens MK, Lennie TA. Symptom clusters predict event-free survival in patients with heart failure. J Cardiovasc Nurs 2010; 25: 284-291.
46. McLachlan GJ. Cluster analysis and related techniques in medical research. Stat Methods Med Res 1992; 1: 27-48.
47. Schulman S. Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thromb Haemost 2012; 108: 872-875.
48. Fox BD, Kahn SR, Langleben D et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012; 345: e7498.
49. Freeman JV, Zhu RP, Owens DK et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Int Med 2011; 154: 1-11.
50. Kansal AR, Sorensen SV, Gani R et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012; 98: 573-578.
51. Lee S, Anglade MW, Pham D et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012; 110: 845-851.
52. Deitelzweig S, Amin A, Jing Y et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ 2012; 15: 776-785.
53. Krejczy M, Harenberg J, Marx S et al. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. Blood 2012; 120 (Suppl): P1164.